The early-stage biotechnology firm Neuron23 has recruited the chief operating officer of Star Therapeutics, Kathy Dong, to join its board of directors.
Founded in 2018, Neuron23 (South San Francisco) specializes in the discovery and development of drugs for neurodegenerative and immunological diseases, drawing insights from data science.
Star Therapeutics (South San Francisco) focuses on the discovery and development of therapeutics that can treat multiple rare diseases.
Before joining Star Therapeutics, Dong worked for a number of pharma companies, including Gilead Sciences, True North Therapeutics and Sanofi.
Kathy Dong
At Gilead, she oversaw the commercial launch of hepatitis B and C therapies such as SOVALDI (sofosbuvir) and HARVONI (ledipasvir/sofosbuvir).
“I am thrilled to welcome someone of Kathy’s caliber and expertise to Neuron23’s board of directors,” said Nancy Staglian…